Showing 7181-7190 of 8194 results for "".
- SkinCeuticals US Taps Christina Fair as New GMhttps://practicaldermatology.com/news/skinceuticals-us-taps-christina-fair-as-new-gm/2457861/Christina (Tina) Fair is the new General Manager at SkinCeuticals US. Tina joins the US team from the SkinCeuticals DMI, where she has been the Vice President of Global Marketing since 2015. During her time in the DMI, Tina led the development o
- Galderma Enters into Long-term Research Agreement on AD with Icahn School of Medicine at Mount Sinai and Northwestern University Feinberg School of Medicinehttps://practicaldermatology.com/news/galderma-enters-into-long-term-research-agreement-on-ad-with-icahn-school-of-medicine-at-mount-sinai-and-northwestern-university-feinberg-school-of-me/2457865/Galderma has signed a joint research agreement on Atopic Dermatitis (AD) with two leading academic institutions—Icahn School of Medicine at Mount Sinai in New York City, and Northwestern University Feinberg School of Medicine in Chicago. This seven-year collaborative agreement aims to enhan
- MainPointe Pharmaceuticals to Purchase and License Mission's Consumer Productshttps://practicaldermatology.com/news/mainpointe-pharmaceuticals-to-purchase-and-license-missions-consumer-products/2457868/Mission Pharmacal Company has recently divested several consumer products to MainPointe Pharmaceuticals, LLC. In addition, the marketing rights of additional consumer products have been licensed by Mission to MainPointe. As part of these transactions, the companies have also entered into a renewa
- Stelara Reduces Aortic Vascular Inflammationhttps://practicaldermatology.com/news/stelara-reduces-aortic-vascular-inflammation/2457880/In addition to its effects on skin inflammation, Stelara (Ustekinumab) reduces aortic inflammation, report researchers from the Perelman School of Medicine at the University of Pennsylvania at the annual meeting of the American Academy of Dermato
- Meet the Newest AAD Officers and Board Membershttps://practicaldermatology.com/news/meet-the-newest-aad-officers-and-board-members/2457876/Suzanne M. Olbricht, MD, FAAD, a Boston-based dermatologist, will take the helm of the American Academy of Dermatology (AAD) as the new President. Her one-year term officially begins on Tuesday, Feb. 20, at the conclusion of the 2018 AAD Annual Meeting in San Diego. Dr. Olbricht is an ass
- Merkel Cell Carcinoma Is On The Risehttps://practicaldermatology.com/news/merkel-cell-carcinoma-is-on-the-rise/2457879/Merkel cell carcinoma (MCC) is on the rise, according to new research published in the Journal of the American Academy of Dermatology and presented at the American Academy of Dermatology 2018 Annual Meetin
- Restoration Robotics to Showcase ARTAS Robotic Hair Restoration System at Annual AAD Meetinghttps://practicaldermatology.com/news/restoration-robotics-to-showcase-artas-robotic-hair-restoration-system-at-annual-aad-meeting/2457882/Restoration Robotics, Inc. will showcase the ARTAS Robotic Hair Restoration System at The Annual Meeting of the American Academy of Dermatology (AAD) February 15-18 at the San Diego Convention Center in San Diego, CA. At the meeting, Restoration Robotics will host in-booth presentations a
- NanOlogy Enrolls First Patient in Clinical Trial for Cutaneous Metastaseshttps://practicaldermatology.com/news/nanology-enrolls-first-patient-in-clinical-trial-for-cutaneous-metastases/2457887/NanOlogy™, a clinical-stage pharmaceutical development company and affiliate of DFB Pharmaceuticals, has enrolled the first patient in a Phase 1/2 clinical trial of a submicron particle paclitaxel topical anhydrous ointment for the treatment of cutaneous metastases. The open label dose esca
- South Beach Symposium to Kick Off March 1https://practicaldermatology.com/news/south-beach-symposium-to-kick-off-march-1/2457895/Now celebrating its 16th year, the 2018 South Beach Symposium (SBS) will feature live demonstration workshops of minimally invasive aesthetic treatments with injectables and devices providing attendees with new skills and techniques th
- FDA Approves Cosentyx Label Update to Include Scalp Psoriasishttps://practicaldermatology.com/news/fda-approves-cosentyx-label-update-to-include-scalp-psoriasis/2457896/The FDA has approved a label update for Novartis' Cosentyx (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis. The updated label includes Cosentyx data in moderate to severe scalp psoriasis—one of the difficult-to-treat for